Cardiological care in the Russian Federation: systemic modernization and transition to risk management

The article presents the consolidated position of leading national medical research centers on the current state and development priorities of cardiological care in the Russian Federation. In recent years, the federal project “Fighting Cardiovascular Diseases” has created a platform for modernizing care for patients with cardiovascular diseases: the infrastructure of regional vascular centers and primary vascular units has been upgraded, patient routing has been improved, access to endovascular and cardiac surgical interventions has expanded, an outpatient drug‑supply framework has been established, dispensary follow‑up has been strengthened, and the practical implementation of digital tools for quality management has begun. The next stage in the development of the service is associated with shifting the focus from responding to established vascular catastrophes to continuous cardiovascular risk management, including early detection of dyslipidemias, subclinical atherosclerosis, and genetically determined high‑risk factors such as lipoprotein(a). Special emphasis is placed on to continuity of care across levels of medical services, the organization of dispensary follow‑up, and the role of clinical practice guidelines, clinical decision support services, electronic medical records, registries, and remote monitoring.

1. Khokhlunov S.M., Kuznetsov D.V. Cardiovascular surgery in the Volga Federal District in 2022. Russian Journal of Thoracic and Cardiovascular Surgery. 2024; 66(1): 29–35 (In Russ.). https://doi.org/10.24022/0236-2791-2024-66-1-29-35

2. Golukhova E.Z., Semenov V.Yu., Milievskaya E.B., Pryanishnikov V.V. Availability of high-technology medical care in cardiovascular surgery for residents of the constituent entities of the Russian Federation in 2021. Complex Issues of Cardiovascular Diseases. 2023; 12(2): 77–87 (In Russ.). https://doi.org/10.17802/2306-1278-2023-12-2-77-87

3. Bokeria L.A., Milievskaya E.B., Pryanishnikov V.V. Cardiovascular surgery – 2024. Diseases and congenital anomalies of the circulatory system. Moscow: Bakulev National Medical Research Center for Cardiovascular Surgery; 2025. 410 p. ISBN 978-5-7982-0478-6. (In Russ.).

4. Golukhova E.Z., Semenov V.Yu., Milievskaya E.B., et al. Implementation of the federal project “Fighting cardiovascular diseases”: surgical aspects and trends in high-tech medical care. Vestnik Roszdravnadzora. 2025; 2: 22–33 (In Russ.).

5. Golukhova E.Z. Report on clinical and research activities of the A.N. Bakulev national medical research center for cardiovascular surgery of the ministry of health of the Russian Federation for 2024. Prospects for Further Development. The Bulletin of Bakoulev Center «Cardiovascular Diseases». 2025; 26 (Special Issue): S5–S130.

6. Kamkin E.G., Karakulina E.V., Astapenko E.M., et al. Preferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects. Russian Journal of Cardiology. 2025; 30(6): 6391 (In Russ.). https://doi.org/10.15829/1560-4071-2025-6391. EDN: TYQUTG

7. Averkov O.V., Harutyunyan G.K., Duplyakov D.V., et al. 2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025; 30(3): 6306 (In Russ.). https://doi.org/10.15829/1560-4071-2025-6306. EDN: IVJCUK

8. Averkov O.V., Harutyunyan G.K., Duplyakov D.V., et al. 2024 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025; 30(5): 6319 (In Russ.). https://doi.org/10.15829/1560-4071-2025-6319. EDN: CXJUIB

9. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011 Nov 15; 58(21): 2241–2247. https://doi.org/10.1016/j.jacc.2011.08.025& PMID: 22078432

10. Bokeria L.A., Shatalov K.V. Pediatric Cardiac Surgery: A Guide for Physicians. Moscow; 2016. 864 p. (In Russ.).

11. Svobodov A.A., Gulasaryan R.S., Armaganova A.A., et al. Application of 3D modeling in surgical planning for complex congenital heart disease. Russian Journal of Thoracic and Cardiovascular Surgery. 2023; 65(1): 119–123 (In Russ.). https://doi.org/10.24022/0236-2791-2023-65-1-119-123

12. Petrosyan K.V., Tokareva E.V. Transcatheter technologies for right ventricular outflow tract obstruction in newborns with complex congenital heart disease. Russian Journal of Thoracic and Cardiovascular Surgery. 2024; 66(4): 445–451 (In Russ.). https://doi.org/10.24022/0236-2791-2024-66-4-445-451

13. Shlyakhto E.V., Nedogoda S.V., Babenko A.Yu., et al. Concept of an interdisciplinary consensus document on cardiovascular-renal-hepatic-metabolic syndrome. Russian Journal of Cardiology. 2025; 30(1S): 6533 (In Russ.). https://doi.org/10.15829/1560-4071-2025-6533

14. Larina V.N., Akhmatova F.D., Arakelov S.E., et al. Modern strategies for cardiac rehabilitation after myocardial infarction and percutaneous coronary intervention. Kardiologiia. 2020; 60(3): 111–118 (In Russ.). https://doi.org/10.18087/cardio.2020.3.n546

15. Khutaeva Z.I., Konovalov G.A. Lipoprotein(a): new approaches to risk assessment and management. Atherosclerosis and Dyslipidemias. 2025; 1(58): 5–12 (In Russ.). https://doi.org/10.34687/2219-8202.JAD.2025.01.0001

16. Voevoda M.I., Ezhov M.V., Konovalov G.A., et al. New opportunities to use a lipoprotein(a) blood test in real-life clinical practice. Resolution of the expert council. Russian Medical Journal. 2024; 9(2): 40–44 (In Russ.). https://doi.org/10.32364/2225-2282-2024-9-7

17. Sosnowska B., Toth P.P., Razavi A.C., et al. 2024: The year in cardiovascular disease – the year of lipoprotein(a). Research advances and new findings. Archives of Medical Science. 2025; 21(2): 355–373. https://doi.org/10.5114/aoms/202213. PMID: 40395905

18. Shah N.P., Mulder H., Lydon E., et al. Lipoprotein(a) testing in patients with atherosclerotic cardiovascular disease in 5 large US health systems. Journal of the American Heart Association. 2024; 13(21): e035610. https://doi.org/10.1161/JAHA.124.035610. PMID: 39494552

19. Kronenberg F., Mora S., Stroes E. S. G., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022 Oct 14; 43(39): 3925–3946. https://doi.org/10.1093/eurheartj/ehac361 PMID: 36036785

20. Thomas P.E., Vedel-Krogh S., Nielsen S.F., et al. Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events. Journal of the American College of Cardiology. 2023; 82(24): 2265–2276. https://doi.org/10.1016/j.jacc.2023.10.009. PMID: 38057068

21. França V., Gomes É.I.L., de Campos E.V.S., et al. Relationship between lipoprotein (a) and subclinical carotid atherosclerosis in asymptomatic individuals. Clinics (Sao Paulo, Brazil). 2022 Sep 27; 77: 100107. https://doi.org/10.1016/j.clinsp.2022.100107. PMID: 36179527

22. Lee H., Park K.S., Jeon Y.J., et al. Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals. Atherosclerosis. 2022 May; 349: 190–195. https://doi.org/10.1016/j.atherosclerosis.2021.09.027. PMID: 34607706

23. Mszar R., Cainzos-Achirica M., Valero-Elizondo J., et al. Lipoprotein(a) and Coronary Plaque in Asymptomatic Individuals: The Miami Heart Study at Baptist Health South Florida. Circulation. Cardiovascular Imaging. 2024 Jul; 17(7): e016152. https://doi.org/10.1161/CIRCIMAGING.123.016152. PMID: 39012945

24. Mehta A., Vasquez N., Ayers C.R., et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. Journal of the American College of Cardiology. 2022; 79(8): 757–768. https://doi.org/10.1016/j.jacc.2021.11. 058. PMID: 35210030

25. Man S., Zu Y., Yang X., et al. Prevalence of elevated lipoprotein(a) and its association with subclinical atherosclerosis in 2.9 million Chinese adults. Journal of the American College of Cardiology. 2025; 85(19): 1979–1992. https://doi.org/10.1016/j.jacc.2025.02.032. PMID: 40266173

26. Chashchin M.G., Khutaeva Z.I., Konovalov G.A., et al. Extremely high lipoprotein (a) as a marker of early atherosclerosis: analysis of a large real-world cohort. Sechenov Medical Journal. 2026; 17(1): 4–17. https://doi.org/10.47093/2218-7332.2026.17.1.4-17

27. Mach F., Koskinas K.C., Roeters van Lennep J.E., et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025; 46(42): 4359–4378. https://doi.org/10.1093/eurheartj/ehaf190. PMID: 40878289

28. Ezhov M.V., Kukharchuk V.V., Balakhonova T.V., et al. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025). Eurasian heart journal. 2025; 2: 6–34 (In Russ.). https://doi.org/10.38109/2225-1685-2025-2-6-34

29. Afanasieva OI, Tyurina AV, Klesareva EA, et al. Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different Equations. Diseases. 2026 Jan 27; 14(2): 41. https://doi.org/10.3390/diseases14020041. PMID: 41745079

30. Pokrovsky S.N., Afanasieva O.I., Safarova M.S., et al. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity. Atherosclerosis Supplements. 2017; 30: 166–173. https://doi.org/10.1016/j.atherosclerosissup.2017.05.004. PMID: 29096833

31. Safarova M.S., Ezhov M.V., Afanasieva O.I., et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements. 2013; 14(1): 93–99. https://doi.org/10.1016/j.atherosclerosissup.2012.10.015. PMID: 23357149

32. Xie S., Galimberti F., Olmastroni E., et al. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis. 2025; 408: 120420. https://doi.org/10.1016/j.atherosclerosis.2025.120420. PMID: 40618457

33. Konovalov G.A., Bazhan S.S. Evolocumab: innovative possibilities for lowering low-density lipoprotein cholesterol, lipoprotein(a), and cardiovascular risk management. Cardiology: News, Opinions, Training. 2017; 2(13): 45–56 (In Russ.).

34. De Los Reyes C., Rikhi R. R., Doherty S., et al. Current Clinical Trials for Treating Elevated Lipoprotein(a). Current Cardiovascular Risk Reports. 2025 Dec; 19(1): 7. https://doi.org/10.1007/s12170-025-00759-8. PMID: 40703143

35. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024; 29(9): 6117 (In Russ.). https://doi.org/10.15829/1560-4071-2024-6117. EDN: GUEWLU

36. Barbarash O.L., Karpov Yu.A., Panov A.V., et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024; 29(9): 6110 (In Russ.). https://doi.org/10.15829/1560-4071-2024-6110. EDN: HHJJUT

37. Golukhova E.Z., Golitsyn S.P., Mikhailov E.N., et al. 2025 Clinical practice guidelines for Atrial fibrillation and flutter. Russian Journal of Cardiology. 2025; 30(11): 6668 (In Russ.). https://doi.org/10.15829/1560-4071-2025-6668. EDN: MGXGON

38. Galyavich A.S., Tereshchenko S.N., Uskach T.M., et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024; 29(11): 6162 (In Russ.). https://doi.org/10.15829/1560-4071-2024-6162. EDN: WKIDLJ

39. Villevalde S.V., Soloveva A.E., Zvartau N.E., et al. Principles of organization of medical care for patients with heart failure in the system of cardiovascular risk management: focus on continuity of care and patient routing. Practical materials. Russian Journal of Cardiology. 2021; 26(3S): 4558 (In Russ.). https://doi.org/10.15829/1560-4071-2021-4558

40. Ageev FT, Blankova ZN, Svirida ON, et al. Care algorithm for patients with chronic heart failure. Five steps to success. Russian Cardiology Bulletin. 2024; 19(3): 6–15 (In Russ.). https://doi.org/10.17116/Cardiobulletin2024190316

41. Villevalde S.V., Zvartau N.E., Yakovlev A.N., et al. Association of medical staffing and outcomes in cardiovascular diseases. Russian Journal of Cardiology. 2020; 25(4S): 4236 (In Russ.). https://doi.org/10.15829/1560-4071-2020-4236

42. Endubaeva G.V., Solovyova A.E., Medvedev A.E., et al. Compliance of the management of hospitalized patients with heart failure with the quality criteria for health care: data from the St. Petersburg registry. Russian Journal of Cardiology. 2023; 28(4S): 5621 (In Russ.). https://doi.org/10.15829/1560-4071-2023-5621. EDN: BBAIJN

43. Astrakova (Benimetskaya) K.S., Mikheenko I.L., Uranov A.E., et al. The impact of clinical decision support systems on adherence to clinical guidelines and achieving target levels of lowdensity lipoprotein cholesterol in patients at risk of developing cardiovascular events (SuccESS). Rational Pharmacotherapy in Cardiology. 2024; 20(6): 625–636. https://doi.org/10.20996/1819-6446-2024-3138. EDN BWLQBK

44. Tereshchenko S.N., Zhirov I.V., Shangina A.M., et al. Impact of a clinical decision support system on adherence to clinical guidelines in the management of patients with heart failure (SPHERA-HF study). Cardiovascular Therapy and Prevention. 2025; 24(7): 4462 (In Russ.). https://doi.org/10.15829/1728-8800-2025-4462. EDN: ZSMLDI